Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?

Yohann Loriot • 5 Jun 2023
ASCO 2023
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Enfortumab vedotin Erdafitinib
EV301 THOR

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, discusses the evolving landscape of urothelial carcinoma management, touching on results from EV-301 (NCT03474107), as well as the use of erdafitinib in patients with advanced or metastatic disease. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yohann Loriot

1:05
Future endeavours with ADCs in bladder cancer
Yohann Loriot • 5 Jun 2023
0:58
ADCs in the management of urothelial carcinoma
Yohann Loriot • 5 Jun 2023
1:22
Safety analysis of TROPHY-U-01 based on UGT1A1 status in mUC
Yohann Loriot • 5 Jun 2023
1:47
THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations
Yohann Loriot • 5 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals